1. A medicament containing trospia for use in treating bladder dysfunction by local administration of trospia to the bladder of a patient in order to achieve a steady concentration of trospia in the urine in the bladder, sufficient to obtain a therapeutic concentration of trospia in the tissues of the bladder. the introduction into the bladder of the patient is carried out with an average dosage of from 0.075 mg / day to approximately 150 mg / day of trospia during the treatment period of s to 180 dney.2. The drug according to claim 1, characterized in that the patient is injected locally into the bladder with an average dosage of 0.15 to 15 mg / day of trospia. 3. The drug according to claim 1 or 2, characterized in that the duration of the treatment period is from 1 to 90 days. The drug according to claim 1 or 2, characterized in that the duration of the treatment period is from 1 to 60 days. The drug according to claim 1, characterized in that the local injection into the patient's bladder is continuous. The drug according to claim 1, characterized in that the local injection into the patient's bladder is periodic. A medicament according to claim 1, characterized in that the trospia enters the bladder from the intravesical drug delivery device, which releases trospia into the urine in the urinary bladder. The medicament according to claim 7, characterized in that the intravesical drug delivery device continuously releases trospia into the urine in the urinary bladder during the treatment period. The drug according to claim 7 or 8, characterized in that1. Лекарственный препарат, содержащий троспий для использования в лечении дисфункции мочевого пузыря посредством локального введения троспия в мочевой пузырь пациента для того, чтобы достичь устойчивой концентрации троспия в моче в мочевом пузыре, достаточной для получения терапевтической концентрации троспия в тканях мочевого пузыря.при этом локальное введение в мочевой пузырь пациента осуществляется при среднем зн
